Bladder Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Bladder Cancer > What Your Doctor is Reading About Bladder Cancer > Immunotherapy

Immunotherapy

1. Bacille Calmette-Guerin intravesical instillation and erectile function: is there a concern?

Author: Sighinolfi MC; Micali S; De Stefani S; Mofferdin A; Ferrari N; Giacometti M; Bianchi G;
Institution: Department of Urology, University of Modena, Modena, Italy.
Journal: Andrologia. 2007 Apr;39(2):51-4.
Abstract URL: Click here to view abstract

2. Immunotherapeutic strategies for high-risk bladder cancer.

Author: Sharma P; Old LJ; Allison JP;
Institution: Department of Genitourinary Medical Oncology and Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. padsharma@mdanderson.org
Journal: Semin Oncol. 2007 Apr;34(2):165-72.
Abstract URL: Click here to view abstract

3. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.

Author: Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED;
Institution: Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. slerner@bcm.tmc.edu
Journal: J Urol. 2007 May;177(5):1727-31.
Abstract URL: Click here to view abstract

4. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P, Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Claude Bernard, 5, France.

Author: Grossman HB;
Institution
Journal: Urol Oncol. 2007 May-Jun;25(3):272.
Abstract URL: Click here to view abstract

5. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer.

Author: Gardmark T; Jahnson S; Wahlquist R; Wijkstrom H; Malmstrom PU;
Institution: Department of Urology, Surgical Sciences, Uppsala, Sweden. truls.gardmark@surgsci.uu.se
Journal: BJU Int. 2007 Apr;99(4):817-20. Epub 2007 Jan 22.
Abstract URL: Click here to view abstract

6. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy.

Author: Herr HW;
Institution: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. herrh@mskcc.org
Journal: Urology. 2007 Jul;70(1):65-8.
Abstract URL: Click here to view abstract

7. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder.

Author: Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M;
Institution: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. atake@med.kobe-u.ac.jp
Journal: Int J Urol. 2008 Apr;15(4):309-13.
Abstract URL: Click here to view abstract

8. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy.

Author: Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J;
Institution: Institute of Urology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel. sdmargel@bezeqint.net
Journal: Urology. 2007 Jan;69(1):78-82.
Abstract URL: Click here to view abstract